Combined galectin-9 and MCP-1 measurements may offer a noninvasive way to better track disease activity and detect kidney ...

Doing puzzles helps columnist Candace Semien temper the onset of lupus symptoms and redefine what work life means to her.

Telitacicept, a B-cell-targeting therapy developed by RemeGen, outperformed a placebo at reducing the severity of systemic lupus erythematosus (SLE) in a Phase 3 clinical trial in China, the company ...

Lupuzor (rigerimod, or IPP-201101) combined with standard therapy did not demonstrate a statistically significant response rate in systemic lupus erythematosus (SLE) patients over standard care alone, ...

Once you receive a diagnosis of lupus, it is difficult to avoid its chronic impact. The disease stays on your mind and affects your perceptions and decisions. You may not be in a flare or “suffering,” ...

Biogen is making “strong progress” with enrollment in the AMETHYST study, a Phase 2/3 clinical trial testing the company’s experimental therapy litifilimab (BIIB059) in people with cutaneous lupus ...

Lupkynis (voclosporin) is now approved in Japan to treat lupus nephritis, a complication of lupus marked by kidney damage and inflammation. The Japanese Ministry of Health, Labour, and Welfare ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit The launch of the placebo-controlled PALIZADE trial (NCT05781750) earlier this year followed the ...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has awarded $3 million to a research team that’s using artificial intelligence (AI) to diagnose lupus nephritis, one of the ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to RemeGen‘s RC18 (telitacicept) to treat people with systemic lupus erythematosus (SLE). A therapy candidate is put on ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google Summer is officially here, and while I’m trying to shield myself ...

Three new Phase 3 clinical trials testing the experimental therapy ianalumab in people with systemic lupus erythematosus (SLE) and lupus nephritis are now recruiting patients. All three trials are ...